These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 2862316)

  • 1. Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine.
    Reingold AL; Broome CV; Hightower AW; Ajello GW; Bolan GA; Adamsbaum C; Jones EE; Phillips C; Tiendrebeogo H; Yada A
    Lancet; 1985 Jul; 2(8447):114-8. PubMed ID: 2862316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control study.
    Noronha CP; Struchiner CJ; Halloran ME
    Int J Epidemiol; 1995 Oct; 24(5):1050-7. PubMed ID: 8557439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Observation on the epidemiologic efficacy for 9 years on epidemic meningococcal polysaccharide vaccine of group A by district immunization method].
    Ma Z
    Zhonghua Liu Xing Bing Xue Za Zhi; 1991 Apr; 12(2):69-71. PubMed ID: 2065343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age.
    Peltola H; Mäkelä H; Käyhty H; Jousimies H; Herva E; Hällström K; Sivonen A; Renkonen OV; Pettay O; Karanko V; Ahvonen P; Sarna S
    N Engl J Med; 1977 Sep; 297(13):686-91. PubMed ID: 408682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy of the meningococcal vaccine from Group C capsular polysaccharide].
    González Enríquez J; García Comas L; Alcaide Jiménez JF; Sáenz Calvo A; Conde Olasagasti J
    Rev Esp Salud Publica; 1997; 71(2):103-26. PubMed ID: 9546855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Preventive effectiveness of an urgent mass vaccination with purified meningococcal polysaccharide vaccine observed during a meningitis epidemic].
    Wu C
    Zhonghua Liu Xing Bing Xue Za Zhi; 1985 Dec; 6(6):344-6. PubMed ID: 3938683
    [No Abstract]   [Full Text] [Related]  

  • 7. Control of epidemic meningococcal meningitis by mass vaccination. II. Persistence of antibody four years after vaccination.
    Mohammed I; Onyemelukwe GC; Obineche EN; Gupta N; Oyeyinka GO
    J Infect; 1984 Sep; 9(2):197-202. PubMed ID: 6438245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Changes in epidemic features of epidemic cerebrospinal meningitis after vaccination with purified meningococcal polysaccharide vaccine group A in Zhengzhou].
    Wiu JJ
    Zhonghua Yu Fang Yi Xue Za Zhi; 1993 May; 27(3):160-1. PubMed ID: 8243180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effectiveness of an immunization campaign with group A and C meningococcal polysaccharide vaccine in controlling an outbreak of group C meningococcal disease].
    Gong J; Li CY; Dong BQ; Huang JZ; Quan Y; Lu WZ; Luo CH; Mao WC; Liao HZ; Fang JS; Cui XL; Xie GL; Wu XH; Lan RW
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Jun; 29(6):552-5. PubMed ID: 19040035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Survey on efficacy of inoculating purified polysaccharide vaccines as an emergency measure in preventing epidemic meningitis].
    Xu CH
    Zhonghua Liu Xing Bing Xue Za Zhi; 1982 Dec; 3(6):328-30. PubMed ID: 6821030
    [No Abstract]   [Full Text] [Related]  

  • 11. Meningococcal disease in catalonia 1 year after mass vaccination campaign with meningococcal group C polysaccharide vaccine.
    Cardeñosa N; Domínguez A; Martínez A; Alvarez J; Pañella H; Godoy P; Minguell S; Camps N; Vázquez JA;
    Infection; 2003 Dec; 31(6):392-7. PubMed ID: 14735381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Control of meningococcal infection in the African meningitis belt by selective vaccination.
    Greenwood BM; Wali SS
    Lancet; 1980 Apr; 1(8171):729-32. PubMed ID: 6103155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway.
    Bjune G; Høiby EA; Grønnesby JK; Arnesen O; Fredriksen JH; Halstensen A; Holten E; Lindbak AK; Nøkleby H; Rosenqvist E
    Lancet; 1991 Nov; 338(8775):1093-6. PubMed ID: 1682541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "Love's labours lost": failure to implement mass vaccination against group A meningococcal meningitis in sub-Saharan Africa.
    Robbins JB; Towne DW; Gotschlich EC; Schneerson R
    Lancet; 1997 Sep; 350(9081):880-2. PubMed ID: 9310615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Application of SP-RIA in the antibody surveillance and serologic diagnosis of epidemic cerebrospinal meningitis].
    Chen X
    Zhonghua Liu Xing Bing Xue Za Zhi; 1993 Dec; 14(6):366-70. PubMed ID: 8156584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emergency vaccination against epidemic meningitis in Ghana: implications for the control of meningococcal disease in West Africa.
    Woods CW; Armstrong G; Sackey SO; Tetteh C; Bugri S; Perkins BA; Rosenstein NE
    Lancet; 2000 Jan; 355(9197):30-3. PubMed ID: 10615888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunologic memory 5 years after meningococcal A/C conjugate vaccination in infancy.
    MacLennan J; Obaro S; Deeks J; Lake D; Elie C; Carlone G; Moxon ER; Greenwood B
    J Infect Dis; 2001 Jan; 183(1):97-104. PubMed ID: 11087205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-marketing study on the safety of a meningococcal group A, C bivalent polysaccharide conjugate vaccine.
    Fu C; Huang G; Cui M; Wang M
    Hum Vaccin Immunother; 2014; 10(1):138-9. PubMed ID: 24013384
    [No Abstract]   [Full Text] [Related]  

  • 19. Editorial retrospective. Meningococcal A and other polysaccharide vaccines. A five-year progress report.
    Lepow ML; Gold R
    N Engl J Med; 1983 May; 308(19):1158-60. PubMed ID: 6403865
    [No Abstract]   [Full Text] [Related]  

  • 20. A serogroup A meningococcal polysaccharide vaccine: studies in the Sudan to combat cerebrospinal meningitis caused by Neisseria meningitidis group A.
    Erwa HH; Haseeb MA; Idris AA; Lapeyssonnie L; Sanborn WR; Sippel JE
    Bull World Health Organ; 1973; 49(3):301-5. PubMed ID: 4211056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.